CRRC Times and Xiamen Xiangyu were among the LPs for the venture firm’s latest dollar vehicle that will invest in healtech companies concentrating on biotech, IVDs and medical supplies.

Alameda Research, Blockchain.com and Coinbase helped cryptocurrency exchange Pintu close a $35m round while small molecule drug developer Aardvark raised $29m.

The Adimab and GV-backed covid-19 antibody treatment developer has floated on Nasdaq at a $1.84bn valuation, about a year after it was founded.

Cigna Ventures returned to back an $83.5m round for the kidney care provider that also featured new investor Blue Shield of California.

The Angelini Lumira Biosciences Fund will invest in early-stage companies in Canada and the US.

JD Health has backed a $93m series D round for Rimag, while a couple of India-based startups delivered exits.

The China Union-backed drug contract manufacturer has raised the funding approximately a year and a half after a $60m series A.

Bayer is set to acquire the precision therapeutics developer backed by Alexandria Venture Investments, Celgene and SoftBank, with another $500m in milestone payments up for grabs.

Alphabet, Eli Lilly, Dong-A ST and Alexandria Real Estate Equities backed the immunotherapy developer in a series B round, which took its overall funding to over $335m.

China Merchants Capital has co-led a series B round sized at almost $99.2m that also attracted existing shareholder Legend Capital.